floxuridine has been researched along with Lung Neoplasms in 120 studies
Floxuridine: An antineoplastic antimetabolite that is metabolized to fluorouracil when administered by rapid injection; when administered by slow, continuous, intra-arterial infusion, it is converted to floxuridine monophosphate. It has been used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract.
floxuridine : A pyrimidine 2'-deoxyribonucleoside compound having 5-fluorouracil as the nucleobase; used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract.
Lung Neoplasms: Tumors or cancer of the LUNG.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Irinotecan (CPT-11) and doxifluridine (5'-DFUR) are active agents against colorectal cancer." | 9.11 | Sequential treatment with irinotecan and doxifluridine: optimal dosing schedule in murine models and in a phase I study for metastatic colorectal cancer. ( Fujimoto-Ouchi, K; Kato, T; Kikkawa, N; Mishima, H; Nishisho, I; Tanaka, Y; Tsujie, M; Tsujinaka, T; Yanagisawa, M, 2005) |
| "The effect of the combination treatment consisted of 5'-deoxy-5-fluorouridine (5'-DFUR) and medroxyprogesterone acetate (MPA) was investigated in 20 recurrent breast cancer patients." | 9.08 | [The effect of combination treatment consisted of 5'-deoxy-5-fluorouridine and medroxyprogesterone acetate for recurrent breast cancer patient]. ( Hayashi, K; Taniguchi, T; Toi, M; Tominaga, T, 1995) |
| "Outpatients with advanced and recurrent breast cancer were treated by a combination therapy of the following drugs: doxifluridine (5'-DFUR) orally administered at a dose of 1200 mg/day; cyclophosphamide (CPA) orally given at dose of 100 mg/day; and tamoxifen (TAM) orally given at dose of 20 mg daily." | 9.07 | [Combination therapy of doxifluridine (5'-DFUR) + cyclophosphamide (CPA) + tamoxifen (TAM) for advanced or recurrent breast cancer. Joint Research Group in the Osaka Area for Combination Therapy of 5'-DFUR with Other Drugs]. ( Irie, K; Kawahara, T; Okumura, T; Ota, J; Sakai, K; Shimoyama, T; Taguchi, T; Terasawa, T; Yamamoto, M; Yasutake, K, 1992) |
| "Two cases of recurrent breast cancer are reported in which chemotherapy with mitoxantrone proved remarkably effective." | 7.70 | [Chemotherapy with mitoxantrone for the treatment of recurrent breast cancer]. ( Katagata, N; Matsuoka, T; Nomizu, T; Takenoshita, S; Tsuchiya, A; Watanabe, F; Yabuta, T; Yamaki, Y, 2000) |
| "Two cases of metastatic breast cancer are reported in which endocrine chemotherapy with Toremifene + 5'-DFUR proved markedly effective." | 7.70 | [Endocrine chemotherapy (high-dose toremifene + 5'-DFUR) found markedly effective for 2 cases of metastatic breast cancer]. ( Kuroda, T; Mizutani, H; Nakamura, Y; Tadaoka, N; Takahashi, N, 1999) |
| "Two cases of recurrent breast cancer, for which combined therapy using toremifene and oral chemotherapeutic agents were effective, are reported." | 7.69 | [Complete tumor regression obtained by chemoendocrine therapy including toremifene in two cases of pulmonary metastasis of breast cancer with a history of tamoxifen treatment]. ( Asanuma, F; Miyagawa, T; Toyoda, H; Uesato, K; Yamada, Y, 1997) |
| "A 72-year-old female with right breast cancer having multiple lung metastases was treated by combined administration of 5'-DFUR at 800 mg/day, and tamoxifen, at 20 mg/day, after standard radical mastectomy." | 7.69 | [A case of advanced breast cancer with multiple lung metastases responding well to postoperative combined administration of doxifluridine (5'-DFUR) and tamoxifen]. ( Akashi, Y; Hachiya, Y; Miyoshi, A; Noshiro, H; Tohma, H, 1994) |
| "Doxifluridine (5-dFUR) is a fluoropyrimidine derivative, which is preferentially converted to 5-fluorouracil (5-FU) within tumour tissues." | 6.68 | Doxifluridine in colorectal cancer patients resistant to 5-fluorouracil (5-FU) containing regimens. ( Artale, S; Bajetta, E; Bignami, P; Buzzoni, R; Del Vecchio, M; Di Bartolomeo, M; Magnani, E; Somma, L; Zunino, F, 1997) |
| "Although most patients with gestational trophoblastic neoplasia (GTN) are cured by conventional chemotherapy, some develop drug resistance or relapse." | 5.37 | Salvage combination chemotherapy with floxuridine, dactinomycin, etoposide, and vincristine (FAEV) for patients with relapsed/chemoresistant gestational trophoblastic neoplasia. ( Feng, F; Geng, S; Wan, X; Wang, T; Xiang, Y, 2011) |
| "To evaluate the antitumor efficacy against metastatic breast cancer of fluoropyrimidines alone and combined with other chemotherapeutic agents, we developed a murine model of breast cancer metastatic to the lung by orthotopically implanting MDA-MB-435S breast tumors into mice." | 5.31 | [Antimetastatic and antitumor effects of fluoropyrimidines alone and combined with taxanes in a murine model of breast cancer metastatic to the lung]. ( Fujioka, A; Fukushima, M; Nakagawa, F; Nukatsuka, M; Ohshimo, H, 2002) |
| "Irinotecan (CPT-11) and doxifluridine (5'-DFUR) are active agents against colorectal cancer." | 5.11 | Sequential treatment with irinotecan and doxifluridine: optimal dosing schedule in murine models and in a phase I study for metastatic colorectal cancer. ( Fujimoto-Ouchi, K; Kato, T; Kikkawa, N; Mishima, H; Nishisho, I; Tanaka, Y; Tsujie, M; Tsujinaka, T; Yanagisawa, M, 2005) |
| "We conducted a multi-center study to investigate the usefulness of a combination drug therapy with doxifluridine (5'-DFUR) and mitomycin C (MMC) in colorectal cancer patients with lung metastasis." | 5.09 | [Combination chemotherapy of doxifluridine plus mitomycin C for colorectal lung metastasis--phase II study]. ( Fujita, H; Hiki, Y; Ike, H; Mitomi, T; Otani, Y; Oya, K; Sadahiro, S; Shimada, H; Yamaguchi, S, 2001) |
| "The effect of the combination treatment consisted of 5'-deoxy-5-fluorouridine (5'-DFUR) and medroxyprogesterone acetate (MPA) was investigated in 20 recurrent breast cancer patients." | 5.08 | [The effect of combination treatment consisted of 5'-deoxy-5-fluorouridine and medroxyprogesterone acetate for recurrent breast cancer patient]. ( Hayashi, K; Taniguchi, T; Toi, M; Tominaga, T, 1995) |
| "Outpatients with advanced and recurrent breast cancer were treated by a combination therapy of the following drugs: doxifluridine (5'-DFUR) orally administered at a dose of 1200 mg/day; cyclophosphamide (CPA) orally given at dose of 100 mg/day; and tamoxifen (TAM) orally given at dose of 20 mg daily." | 5.07 | [Combination therapy of doxifluridine (5'-DFUR) + cyclophosphamide (CPA) + tamoxifen (TAM) for advanced or recurrent breast cancer. Joint Research Group in the Osaka Area for Combination Therapy of 5'-DFUR with Other Drugs]. ( Irie, K; Kawahara, T; Okumura, T; Ota, J; Sakai, K; Shimoyama, T; Taguchi, T; Terasawa, T; Yamamoto, M; Yasutake, K, 1992) |
| "High-dose toremifene therapy (120 mg/day) is useful for the recurrence of receptor-positive breast cancer." | 3.74 | [Evaluation of combination therapy of high-dose toremifene and oral chemotherapy]. ( Murakami, S; Yamamoto, Y, 2007) |
| "A 42-year-old woman with multiple organ metastases from breast cancer was successfully treated with 5'-deoxy-5-fluorouridine (5'-DFUR) and hormonal therapy (leuprorelin+tamoxifen)." | 3.73 | [A case of recurrent breast cancer with multiple lung, adrenal, inferior vena cava tumor thrombus and bone metastases successfully treated with 5'-DFUR and hormonal therapy]. ( Fukami, Y; Hasegawa, H; Hiromatsu, T; Itazu, K; Kawai, K; Komatsu, S; Sakamoto, E; Tabata, T, 2005) |
| " Using a murine dorsal air sac (DAS) assay, we have previously shown that UFT and its metabolites, gamma-hydroxybutyric acid (GHB) and 5-fluorouracil (5-FU), inhibited the angiogenesis induced by murine renal cell carcinoma." | 3.71 | gamma-Hydroxybutyric acid and 5-fluorouracil, metabolites of UFT, inhibit the angiogenesis induced by vascular endothelial growth factor. ( Aoyagi, K; Basaki, Y; Chikahisa, L; Hashimoto, A; Miyadera, K; Okabe, S; Wierzba, K; Yamada, Y; Yonekura, K, 2001) |
| "Two cases of metastatic breast cancer are reported in which endocrine chemotherapy with Toremifene + 5'-DFUR proved markedly effective." | 3.70 | [Endocrine chemotherapy (high-dose toremifene + 5'-DFUR) found markedly effective for 2 cases of metastatic breast cancer]. ( Kuroda, T; Mizutani, H; Nakamura, Y; Tadaoka, N; Takahashi, N, 1999) |
| "Two cases of recurrent breast cancer are reported in which chemotherapy with mitoxantrone proved remarkably effective." | 3.70 | [Chemotherapy with mitoxantrone for the treatment of recurrent breast cancer]. ( Katagata, N; Matsuoka, T; Nomizu, T; Takenoshita, S; Tsuchiya, A; Watanabe, F; Yabuta, T; Yamaki, Y, 2000) |
| "A 72-year-old female with right breast cancer having multiple lung metastases was treated by combined administration of 5'-DFUR at 800 mg/day, and tamoxifen, at 20 mg/day, after standard radical mastectomy." | 3.69 | [A case of advanced breast cancer with multiple lung metastases responding well to postoperative combined administration of doxifluridine (5'-DFUR) and tamoxifen]. ( Akashi, Y; Hachiya, Y; Miyoshi, A; Noshiro, H; Tohma, H, 1994) |
| "Two cases of recurrent breast cancer, for which combined therapy using toremifene and oral chemotherapeutic agents were effective, are reported." | 3.69 | [Complete tumor regression obtained by chemoendocrine therapy including toremifene in two cases of pulmonary metastasis of breast cancer with a history of tamoxifen treatment]. ( Asanuma, F; Miyagawa, T; Toyoda, H; Uesato, K; Yamada, Y, 1997) |
| "When given orally in combination with L-cysteine, 5'-deoxy-5-fluorouridine (DFUR) brought about a significant reduction in the growth of adenocarcinoma 755 and a significant prolongation of life-span in mice bearing Lewis lung carcinoma without increased toxicity to the host as compared with DFUR alone, though L-cysteine alone did not show an appreciable antitumor activity." | 3.67 | Enhanced antitumor effect of 5'-deoxy-5-fluorouridine by oral administration with L-cysteine. ( Araki, E; Hoshi, A; Iigo, M; Nakajima, Y, 1989) |
| "Gemcitabine was rapidly cleared from plasma and undetectable after 3 h." | 2.75 | Pharmacokinetics of gemcitabine in non-small-cell lung cancer patients: impact of the 79A>C cytidine deaminase polymorphism. ( Boezen, HM; de Vries, EG; Groen, HJ; Maring, JG; Maurer, JM; Slijfer, M; Uges, DR; Wachters, FM, 2010) |
| "Patients with advanced or recurrent breast cancer within 1 regimen of prior chemotherapy and without prior use of both Docetaxel and 5'-DFUR were enrolled." | 2.72 | [Evaluation of safety and efficacy for bi-weekly Docetaxel and 5'-DFUR combination therapy in patients with advanced or recurrent breast cancer--Phase I study]. ( Ikeda, M; Ishiguro, K; Kataoka, T; Komaki, K; Kurebayashi, J; Morimoto, T; Sonoo, H; Tanaka, K; Tangoku, A; Yoshizawa, K, 2006) |
| "Doxifluridine (5-dFUR) is a fluoropyrimidine derivative, which is preferentially converted to 5-fluorouracil (5-FU) within tumour tissues." | 2.68 | Doxifluridine in colorectal cancer patients resistant to 5-fluorouracil (5-FU) containing regimens. ( Artale, S; Bajetta, E; Bignami, P; Buzzoni, R; Del Vecchio, M; Di Bartolomeo, M; Magnani, E; Somma, L; Zunino, F, 1997) |
| "Doxifluridine is a fluoropyrimidine derivate which can be administered orally with very low toxicities." | 2.68 | Phase II study of oral doxifluridine in elderly patients with advanced non-small-cell lung cancer. ( Baldini, E; Ceribelli, A; Comella, G; Conte, PF; Falcone, A; Pfanner, E; Ricci, S; Sarcina, R; Stampino, CG; Tibaldi, C, 1996) |
| "Mucositis and diarrhea are the dose-limiting toxicities when continuous infusions of FUdR and high-dose folinic acid are combined with oral hydroxyurea, effects that are consistent with the observed toxicities for FUdR when administered alone or in combination with leucovorin." | 2.67 | Phase I study of 5-day continuous infusion fluorodeoxyuridine and high-dose folinic acid with oral hydroxyurea. ( Ahn, C; Akman, SA; Doroshow, JH; Leong, LA; Margolin, KA; Morgan, RJ; Newman, E; Raschko, JW; Somlo, G, 1994) |
| "Although most patients with gestational trophoblastic neoplasia (GTN) are cured by conventional chemotherapy, some develop drug resistance or relapse." | 1.37 | Salvage combination chemotherapy with floxuridine, dactinomycin, etoposide, and vincristine (FAEV) for patients with relapsed/chemoresistant gestational trophoblastic neoplasia. ( Feng, F; Geng, S; Wan, X; Wang, T; Xiang, Y, 2011) |
| "Gemcitabine was rapidly eliminated from plasma even in patients with renal dysfunction." | 1.35 | Measurement of plasma concentration of gemcitabine and its metabolite dFdU in hemodialysis patients with advanced urothelial cancer. ( Hirobe, M; Itoh, T; Kunishima, Y; Masumori, N; Takayanagi, A; Takeuchi, M; Tsukamoto, T, 2008) |
| "Many patients with gastric cancer respond to TS-1, but some fail to respond or have recurrence." | 1.34 | Doxifluridine combined with weekly paclitaxel for second-line treatment in patients with gastric cancer resistant to TS-1. ( Arai, W; Haruta, H; Hirashima, Y; Hosoya, Y; Hyodo, M; Kurashina, K; Nagai, H; Saito, S; Sakuma, K; Yasuda, Y; Yokoyama, T; Zuiki, T, 2007) |
| "The data on 307 patients with colorectal cancer at stage II or III, who underwent potentially curative resection with lymphadenectomy, were reviewed." | 1.33 | The MMP-9 expression determined the efficacy of postoperative adjuvant chemotherapy using oral fluoropyrimidines in stage II or III colorectal cancer. ( Ikeda, S; Ishibashi, N; Matono, K; Mizobe, T; Ogata, Y; Ogo, S; Ohkita, A; Ozasa, H; Sasatomi, T; Shirouzu, K, 2006) |
| " Pharmacokinetic studies after administration of S-1 revealed high and prolonged plasma 5-FU levels." | 1.32 | S-1-induced, prolonged complete regression of lung metastasis from gastric cancer refractory to 5'-DFUR: a case report with pharmacokinetic study. ( Ajani, JA; Itoh, N; Itoi, H; Shirasaka, T; Ueda, Y; Yamagishi, H; Yamashita, T, 2004) |
| "To evaluate the antitumor efficacy against metastatic breast cancer of fluoropyrimidines alone and combined with other chemotherapeutic agents, we developed a murine model of breast cancer metastatic to the lung by orthotopically implanting MDA-MB-435S breast tumors into mice." | 1.31 | [Antimetastatic and antitumor effects of fluoropyrimidines alone and combined with taxanes in a murine model of breast cancer metastatic to the lung]. ( Fujioka, A; Fukushima, M; Nakagawa, F; Nukatsuka, M; Ohshimo, H, 2002) |
| " The clinical evaluation of UCN-01 combined with 5-fluoropyrimidines may be of interest." | 1.31 | Biochemical and molecular effects of UCN-01 in combination with 5-fluorodeoxyuridine in A431 human epidermoid cancer cells. ( Danenberg, KD; Danenberg, PV; Grem, JL; Kao, V; Nguyen, D, 2002) |
| "Three patients with colorectal cancer and pulmonary metastasis who had previously undergone surgical treatment, were treated by combination chemotherapy with CDDP and 5-FU regimen, but the growth of the metastatic tumor could not be controlled finally." | 1.30 | [Three cases of colorectal cancer with lung metastasis successfully treated with combination chemotherapy using 5'-DFUR and MMC]. ( Horie, H; Hosoya, Y; Ishizuka, T; Kanazawa, K; Kashiwagi, H; Kojima, M; Konishi, H; Shitou, K, 1998) |
| "We report a 68-year-old man with rectal cancer and recurrent pulmonary metastasis treated with concomitant 5'-DFUR + MMC, which resulted in an extreme reduction of the lesion." | 1.30 | [Combination of 5'-DFUR and MMC for recurrent rectal cancer with pulmonary metastasis]. ( Aihara, S; Hiki, Y; Ishikawa, H; Kakita, A; Kanazawa, H; Ohtani, Y, 1999) |
| "Multiple liver and lung metastasis of breast cancer were diagnosed because of high CA 15/3 serum levels and normal gastrointestinal study." | 1.30 | [Effective chemo-endocrine combination therapy for obstructive-jaundice caused by multiple liver metastasis of recurrent breast cancer--a case report]. ( Hoshino, K; Ikeda, H; Koyama, T; Morishita, Y; Nakamura, M, 1999) |
| "Its efficacy for lung metastases from colorectal cancer is known." | 1.30 | [PyNPase activity in primary and metastatic colorectal cancer]. ( Doi, O; Furukawa, H; Hiratsuka, M; Imaoka, S; Ishikawa, O; Iwanaga, T; Kabuto, T; Kameyama, M; Nakamori, S; Ohigashi, H; Sasaki, Y; Yasuda, T; Yokouchi, H, 1997) |
| " Pharmacokinetic evaluation demonstrated that ILP at 21 mg/mL maximally elevated total lung FUDR and 5-fluorouracil levels (508." | 1.29 | Isolated lung perfusion with FUDR in the rat: pharmacokinetics and survival. ( Burt, ME; Ellis, JL; Lenert, JT; Nawata, S; Ng, B; Port, JL, 1996) |
| "A recurrence of colon cancer developed in the left lower lung 16 months after surgery, and 5'-DFUR was administered at a dose of 1,600 mg/body/day." | 1.29 | [A case of pulmonary metastasis from colon cancer successfully treated with high-dose 5'-DFUR]. ( Fujimoto, T; Iihara, K; Kitada, M; Murotani, M; Okumura, Y; Shibata, T; Takada, T; Takami, M; Tsukahara, Y; Watanabe, T, 1995) |
| "Since cancer is mainly a disease of older persons, the incidence of malignancies of all types is expected to increase during the coming decades." | 1.29 | [Chemotherapy for older cancer patients]. ( Urushizaki, I, 1993) |
| "A total of 42 patients with metastatic renal cell carcinoma received floxuridine infusion for 14 days at monthly intervals." | 1.28 | Circadian infusion of floxuridine in patients with metastatic renal cell carcinoma. ( Amato, R; Dexeus, FH; Kilbourn, R; Kwan, J; Logothetis, CJ; Newman, RA; Ogden, S; Sella, A; Striegel, A, 1991) |
| "A woman born in 1924 with colon cancer initially operated on approximately four years ago showed a second recurrence in the lung." | 1.28 | [A case of pulmonary metastasis from colon cancer responding completely to high-dose 5'-DFUR plus MMC combination chemotherapy]. ( Kawahara, T; Kikkawa, N; Kobayakawa, K; Tsuchiya, Y; Tsumura, I, 1991) |
| "The authors treated 42 metastatic renal cell carcinoma (RCC) patients who had received no previous chemotherapy or radiation therapy with circadian venous continuous infusion of 5-fluoro-2-deoxyuridine (FUDR)." | 1.28 | Circadian continuous chemotherapy of renal cell carcinoma with an implantable, programmable infusion pump. ( Bonalumi, MG; Comeri, G; Damascelli, B; Del Nero, A; Garbagnati, F; Lutman, R; Marchianò, A; Mauri, M; Salvetti, M; Spreafico, C, 1990) |
| "A 68-year-old male, who had advanced rectal cancer with multiple pulmonary metastases, had undergone resection of rectal cancer operatively and was treated with a combination chemotherapy using 5'-DFUR (5'-deoxy-5-fluorouridine) and MMC (mitomycin C) for multiple pulmonary metastases." | 1.28 | [A case of multiple pulmonary metastases from rectal cancer which responded completely to combination chemotherapy using 5'-DFUR and MMC]. ( Baba, K; Kawano, H; Matsuda, M; Matsuoka, Y; Morinaga, H; Nagao, K; Nagase, H; Nishimura, R; Ueno, Y, 1989) |
| "We found that this conversion in human tumors was catalyzed not by uridine phosphorylase but by thymidine phosphorylase." | 1.27 | [5'-Deoxy-5-fluorouridine enzymatic activation from the masked compound to 5-fluorouracil in human malignant tissues]. ( Hara, Y, 1984) |
| "Three patients with primary hepatocellular carcinoma demonstrated less than 50% reduction in tumor size." | 1.27 | Assessment of treatment of intrahepatic malignancies using chemotherapy via an implantable pump. ( Jones, LS; McCune, CS; Schwartz, SI, 1985) |
| " The optimal dosage for a phase II study was suggested to be less than 2,100 mg/body/day." | 1.27 | [Phase I study of 5'-deoxy-5-fluorouridine (5'-DFUR)]. ( Furue, H; Kanamaru, R; Kimura, K; Komita, T; Murakami, M; Nakao, I; Ohta, K; Saito, T; Wakui, A; Yokoyama, M, 1985) |
| " In tumor tissue, optimal doses of FUra or FdUrd resulted in lower (a) FdUMP levels (5- to 2-fold), (b) RNA-level antimetabolites (6- to 3-fold), and (c) DNA-level antimetabolites (10- to 4-fold) compared to an optimal dosage of FdCyd plus H4Urd." | 1.27 | Tumor-selective metabolism of 5-fluoro-2'-deoxycytidine coadministered with tetrahydrouridine compared to 5-fluorouracil in mice bearing Lewis lung carcinoma. ( Boothman, DA; Briggle, TV; Greer, S, 1987) |
| " 5'-DFUR was less toxic to immune organs and the functions than those by other fluorinated pyrimidines." | 1.27 | [Antitumor activity and toxicity to the immune system and intestine, of the fluorinated pyrimidines FUra, 5'-DFUR, tegafur and UFT]. ( Fujimoto, K; Ishitsuka, H; Matsuura, N; Miwa, M; Ninomiya, Y; Ryu, M, 1988) |
| "Our results indicate that metastatic renal cell cancer responds to infusional chemotherapy and that the circadian shape of infusion markedly affects our ability to deliver effective doses." | 1.27 | Circadian-based infusional chrono-chemotherapy controls progressive metastatic renal cell carcinoma. ( Fraley, EE; Hrushesky, WJ; Rabatin, JT; Von Roemeling, R, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 43 (35.83) | 18.7374 |
| 1990's | 37 (30.83) | 18.2507 |
| 2000's | 33 (27.50) | 29.6817 |
| 2010's | 7 (5.83) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ajmera, S | 1 |
| Bapat, AR | 1 |
| Danenberg, K | 1 |
| Danenberg, PV | 2 |
| Li, S | 1 |
| He, N | 1 |
| Li, W | 1 |
| Wu, PH | 1 |
| Kumar, R | 1 |
| Han, J | 1 |
| Lim, HJ | 1 |
| Ren, WX | 1 |
| Lim, JY | 1 |
| Kim, JH | 1 |
| Kim, JS | 1 |
| Maring, JG | 1 |
| Wachters, FM | 1 |
| Slijfer, M | 1 |
| Maurer, JM | 1 |
| Boezen, HM | 1 |
| Uges, DR | 1 |
| de Vries, EG | 1 |
| Groen, HJ | 1 |
| Feng, F | 1 |
| Xiang, Y | 1 |
| Wan, X | 1 |
| Geng, S | 1 |
| Wang, T | 1 |
| Toya, H | 1 |
| Takeyoshi, I | 1 |
| Arakawa, K | 1 |
| Sunose, Y | 1 |
| Yoshinari, D | 1 |
| Totsuka, O | 1 |
| Ogawa, H | 1 |
| Hirai, K | 1 |
| Connelly, L | 1 |
| Barham, W | 1 |
| Onishko, HM | 1 |
| Chen, L | 1 |
| Sherrill, TP | 1 |
| Zabuawala, T | 1 |
| Ostrowski, MC | 1 |
| Blackwell, TS | 1 |
| Yull, FE | 1 |
| Wilson, PM | 1 |
| LaBonte, MJ | 1 |
| Lenz, HJ | 1 |
| Mack, PC | 1 |
| Ladner, RD | 1 |
| Ojima, E | 1 |
| Miki, C | 1 |
| Hatada, T | 1 |
| Inoue, Y | 1 |
| Mohri, T | 1 |
| Azuma, T | 1 |
| Kusunoki, M | 1 |
| Sawada, M | 1 |
| Ono, Y | 1 |
| Fukushima, M | 3 |
| Fujiwara, S | 1 |
| Noguchi, T | 2 |
| Suehiro, S | 1 |
| Kikuchi, R | 1 |
| Uchida, Y | 1 |
| ANSFIELD, FJ | 1 |
| CURRERI, AR | 1 |
| SULLIVAN, RD | 2 |
| ZUREK, WZ | 1 |
| WILSON, WL | 1 |
| DELAGARZA, JG | 1 |
| Tomono, H | 1 |
| Kitamura, H | 1 |
| Iwase, M | 1 |
| Kuze, S | 1 |
| Ohi, S | 1 |
| Itoh, Y | 1 |
| Nakazawa, H | 1 |
| Fujita, H | 2 |
| Oya, J | 1 |
| Ishii, K | 1 |
| Tsugawa, K | 1 |
| Nakamura, M | 2 |
| Ohnishi, I | 1 |
| Miwa, K | 1 |
| Nishina, T | 1 |
| Hyodo, I | 1 |
| Miyaike, J | 1 |
| Inaba, T | 1 |
| Suzuki, S | 2 |
| Shiratori, Y | 1 |
| Ueda, Y | 1 |
| Yamagishi, H | 1 |
| Yamashita, T | 1 |
| Itoh, N | 1 |
| Itoi, H | 1 |
| Shirasaka, T | 1 |
| Ajani, JA | 1 |
| Mishima, H | 1 |
| Kato, T | 1 |
| Yanagisawa, M | 1 |
| Tsujinaka, T | 1 |
| Nishisho, I | 1 |
| Tsujie, M | 1 |
| Fujimoto-Ouchi, K | 2 |
| Tanaka, Y | 3 |
| Kikkawa, N | 3 |
| Sakamoto, E | 1 |
| Hasegawa, H | 1 |
| Komatsu, S | 1 |
| Hiromatsu, T | 1 |
| Itazu, K | 1 |
| Tabata, T | 1 |
| Kawai, K | 1 |
| Fukami, Y | 1 |
| Takechi, T | 1 |
| Okabe, H | 1 |
| Ikeda, K | 1 |
| Fujioka, A | 2 |
| Nakagawa, F | 2 |
| Ohshimo, H | 2 |
| Kitazato, K | 1 |
| Sawada, T | 1 |
| Nishimura, M | 1 |
| Hirose, K | 1 |
| Ogata, Y | 2 |
| Matono, K | 2 |
| Sasatomi, T | 2 |
| Ishibashi, N | 2 |
| Ohkita, A | 1 |
| Mizobe, T | 1 |
| Ogo, S | 1 |
| Ikeda, S | 1 |
| Ozasa, H | 1 |
| Shirouzu, K | 2 |
| Mizutani, S | 1 |
| Oyama, T | 1 |
| Hatanaka, N | 1 |
| Uchikoshi, F | 1 |
| Yoshidome, K | 1 |
| Tori, M | 1 |
| Ueshima, S | 1 |
| Okuma, K | 1 |
| Hiraoka, K | 1 |
| Yamagami, Y | 1 |
| Takahashi, H | 1 |
| Sueyoshi, K | 1 |
| Taira, M | 1 |
| Nakahara, M | 1 |
| Nakao, K | 1 |
| Sekikawa, K | 1 |
| Fujita, S | 1 |
| Abe, N | 1 |
| Ishigame, T | 1 |
| Okada, R | 1 |
| Gonda, K | 1 |
| Saito, M | 1 |
| Onogi, H | 1 |
| Ohki, S | 1 |
| Takenoshita, S | 2 |
| Ikeda, M | 1 |
| Sonoo, H | 1 |
| Tanaka, K | 1 |
| Kurebayashi, J | 1 |
| Morimoto, T | 1 |
| Tangoku, A | 1 |
| Komaki, K | 1 |
| Kataoka, T | 1 |
| Ishiguro, K | 1 |
| Yoshizawa, K | 1 |
| Nozawa, K | 1 |
| Oomi, T | 1 |
| Nakamura, K | 1 |
| Aoyagi, Y | 1 |
| Hayama, T | 1 |
| Yamada, H | 1 |
| Haku, K | 1 |
| Matsuda, K | 1 |
| Mimura, T | 1 |
| Watanabe, T | 2 |
| Arai, W | 1 |
| Hosoya, Y | 2 |
| Hyodo, M | 1 |
| Haruta, H | 1 |
| Kurashina, K | 1 |
| Saito, S | 1 |
| Hirashima, Y | 1 |
| Yokoyama, T | 1 |
| Zuiki, T | 1 |
| Sakuma, K | 1 |
| Yasuda, Y | 1 |
| Nagai, H | 1 |
| Murakami, S | 1 |
| Yamamoto, Y | 2 |
| Marangon, E | 1 |
| Sala, F | 1 |
| Caffo, O | 1 |
| Galligioni, E | 1 |
| D'Incalci, M | 1 |
| Zucchetti, M | 1 |
| Masumori, N | 1 |
| Kunishima, Y | 1 |
| Hirobe, M | 1 |
| Takeuchi, M | 1 |
| Takayanagi, A | 1 |
| Tsukamoto, T | 1 |
| Itoh, T | 1 |
| Takiuchi, H | 1 |
| Goto, M | 1 |
| Imamura, H | 1 |
| Furukawa, H | 2 |
| Imano, M | 1 |
| Imamoto, H | 1 |
| Kimura, Y | 1 |
| Ishida, H | 1 |
| Fujitani, K | 1 |
| Narahara, H | 1 |
| Shimokawa, T | 1 |
| Hartmann, HR | 3 |
| Matter, A | 1 |
| Barone, RM | 1 |
| Byfield, JE | 1 |
| Goldfarb, PB | 1 |
| Frankel, S | 1 |
| Ginn, C | 1 |
| Greer, S | 2 |
| Chu, MY | 1 |
| Naguib, FN | 1 |
| Iltzsch, MH | 1 |
| el Kouni, MH | 1 |
| Chu, SH | 1 |
| Cha, S | 1 |
| Calabresi, P | 2 |
| Malet-Martino, MC | 1 |
| Martino, R | 1 |
| Lopez, A | 1 |
| Béteille, JP | 1 |
| Bon, M | 1 |
| Bernadou, J | 1 |
| Armand, JP | 1 |
| Hara, Y | 1 |
| Shimizu, E | 1 |
| Saijo, N | 2 |
| Eguchi, K | 1 |
| Shinkai, T | 1 |
| Tominaga, K | 1 |
| Sasaki, Y | 2 |
| Fujita, J | 1 |
| Nomori, H | 1 |
| Hoshi, A | 2 |
| Bollag, W | 2 |
| Urushizaki, I | 1 |
| Wong, MK | 1 |
| Bjarnason, GA | 1 |
| Hrushesky, WJ | 3 |
| Webster, P | 1 |
| Morava-Protzner, I | 1 |
| Towers, M | 1 |
| Toi, M | 1 |
| Taniguchi, T | 1 |
| Hayashi, K | 1 |
| Tominaga, T | 1 |
| Ishikawa, T | 2 |
| Ura, M | 1 |
| Yamamoto, T | 1 |
| Ishitsuka, H | 4 |
| Ng, B | 2 |
| Lenert, JT | 2 |
| Weksler, B | 2 |
| Port, JL | 2 |
| Ellis, JL | 2 |
| Burt, ME | 2 |
| Fujimoto, T | 1 |
| Takami, M | 1 |
| Okumura, Y | 1 |
| Takada, T | 1 |
| Kitada, M | 1 |
| Tsukahara, Y | 1 |
| Shibata, T | 1 |
| Murotani, M | 1 |
| Iihara, K | 1 |
| Mori, A | 1 |
| Kennel, SJ | 1 |
| van Borssum Waalkes, M | 1 |
| Scherphof, GL | 1 |
| Huang, L | 1 |
| Senga, O | 1 |
| Miyakawa, M | 1 |
| Hikita, H | 1 |
| Horigome, N | 1 |
| Kouzu, S | 1 |
| Kuwae, K | 1 |
| Hanaoka, T | 1 |
| Yoshida, K | 1 |
| Raschko, JW | 1 |
| Akman, SA | 1 |
| Leong, LA | 1 |
| Margolin, KA | 1 |
| Morgan, RJ | 1 |
| Newman, E | 1 |
| Somlo, G | 1 |
| Ahn, C | 1 |
| Doroshow, JH | 1 |
| Tohma, H | 1 |
| Noshiro, H | 1 |
| Hachiya, Y | 1 |
| Akashi, Y | 1 |
| Miyoshi, A | 1 |
| Tamura, S | 1 |
| Mori, K | 1 |
| Eda, H | 2 |
| Ninomiya, Y | 2 |
| Kodama, I | 1 |
| Aoyagi, K | 2 |
| Tanaka, T | 1 |
| Kumegawa, H | 1 |
| Ohta, J | 1 |
| Maruiwa, M | 1 |
| Kofuji, K | 1 |
| Takeda, J | 1 |
| Kakegawa, T | 1 |
| Tsumura, I | 2 |
| Nawata, S | 1 |
| Baldini, E | 1 |
| Tibaldi, C | 1 |
| Pfanner, E | 1 |
| Ricci, S | 1 |
| Falcone, A | 1 |
| Ceribelli, A | 1 |
| Sarcina, R | 1 |
| Comella, G | 1 |
| Stampino, CG | 1 |
| Conte, PF | 1 |
| Kameyama, M | 2 |
| Nakamori, S | 1 |
| Imaoka, S | 1 |
| Yasuda, T | 1 |
| Ohigashi, H | 1 |
| Hiratsuka, M | 1 |
| Kabuto, T | 1 |
| Ishikawa, O | 1 |
| Iwanaga, T | 1 |
| Yokouchi, H | 1 |
| Doi, O | 1 |
| Bajetta, E | 1 |
| Di Bartolomeo, M | 1 |
| Somma, L | 1 |
| Del Vecchio, M | 1 |
| Artale, S | 1 |
| Zunino, F | 1 |
| Bignami, P | 1 |
| Magnani, E | 1 |
| Buzzoni, R | 1 |
| Yamada, Y | 2 |
| Miyagawa, T | 1 |
| Toyoda, H | 1 |
| Uesato, K | 1 |
| Asanuma, F | 1 |
| Burt, M | 1 |
| Onishi, Y | 1 |
| Hatae, M | 1 |
| Konishi, H | 1 |
| Horie, H | 1 |
| Ishizuka, T | 1 |
| Shitou, K | 1 |
| Kojima, M | 1 |
| Kashiwagi, H | 1 |
| Kanazawa, K | 1 |
| Nakagawa, H | 1 |
| Yamada, M | 2 |
| Maeda, N | 1 |
| Iwatsuki, K | 1 |
| Tsuzuki, T | 1 |
| Hirayama, A | 1 |
| Yamamoto, H | 1 |
| Ikenaka, K | 1 |
| Ohtani, Y | 1 |
| Ishikawa, H | 1 |
| Aihara, S | 1 |
| Kanazawa, H | 1 |
| Hiki, Y | 2 |
| Kakita, A | 1 |
| Hoshino, K | 1 |
| Ikeda, H | 1 |
| Koyama, T | 1 |
| Morishita, Y | 1 |
| Tadaoka, N | 1 |
| Nakamura, Y | 1 |
| Mizutani, H | 1 |
| Kuroda, T | 1 |
| Takahashi, N | 1 |
| Muto, A | 1 |
| Miyazawa, M | 1 |
| Kashimura, S | 1 |
| Kanzaki, N | 1 |
| Kawahara, Y | 1 |
| Sato, M | 1 |
| Kanno, A | 1 |
| Ashino, Y | 1 |
| Matsuoka, T | 1 |
| Nomizu, T | 1 |
| Yabuta, T | 1 |
| Katagata, N | 1 |
| Watanabe, F | 1 |
| Yamaki, Y | 1 |
| Tsuchiya, A | 1 |
| Iwata, H | 1 |
| Mizutani, M | 1 |
| Iwase, T | 1 |
| Murai, H | 1 |
| Miura, S | 1 |
| Katayama, A | 1 |
| Mafune, K | 1 |
| Makuuchi, M | 1 |
| Maruyama, S | 1 |
| Okumoto, T | 1 |
| Kawasaki, K | 1 |
| Ino, H | 1 |
| Kanaya, Y | 1 |
| Otani, J | 1 |
| Yokoyama, N | 1 |
| Soda, M | 1 |
| Sasaki, K | 1 |
| Takasaka, H | 1 |
| Kawasaki, H | 1 |
| Oono, K | 1 |
| Nakayama, I | 1 |
| Matsunaga, T | 1 |
| Takaoka, A | 1 |
| Aoki, S | 1 |
| Hamamatsu, C | 1 |
| Hirayama, T | 1 |
| Nakagawa, N | 1 |
| Shibata, K | 1 |
| Yabana, T | 1 |
| Hirata, K | 2 |
| Ike, H | 1 |
| Sadahiro, S | 1 |
| Oya, K | 1 |
| Otani, Y | 1 |
| Shimada, H | 1 |
| Yamaguchi, S | 1 |
| Mitomi, T | 1 |
| Araki, Y | 1 |
| Nozoe, Y | 1 |
| Miyagi, Y | 1 |
| Nakagawa, M | 1 |
| Kishimoto, Y | 1 |
| Hayashi, A | 1 |
| Mituoka, M | 1 |
| Konishi, J | 1 |
| Kitahara, S | 1 |
| Ogata, H | 1 |
| Katagiri, T | 1 |
| Nonaka, K | 1 |
| Shiba, T | 1 |
| Nukatsuka, M | 1 |
| Basaki, Y | 1 |
| Chikahisa, L | 1 |
| Miyadera, K | 1 |
| Yonekura, K | 1 |
| Hashimoto, A | 1 |
| Okabe, S | 1 |
| Wierzba, K | 1 |
| Grem, JL | 1 |
| Danenberg, KD | 1 |
| Kao, V | 1 |
| Nguyen, D | 1 |
| Poirier, LA | 1 |
| Stoner, GD | 1 |
| Shimkin, MB | 1 |
| Schabel, FM | 1 |
| Tsukeda, H | 1 |
| Mizuno, S | 1 |
| Nitta, K | 1 |
| Abrams, DN | 2 |
| Knaus, EE | 5 |
| Lentle, BC | 1 |
| Wiebe, LI | 5 |
| Sugimoto, Y | 1 |
| Ohe, Y | 1 |
| Nishio, K | 1 |
| Ohmori, T | 1 |
| Fujiwara, Y | 1 |
| Hashimoto, T | 1 |
| Araki, H | 1 |
| Yoshioka, T | 1 |
| Yasui, K | 1 |
| Kodama, M | 1 |
| Ota, J | 1 |
| Taguchi, T | 1 |
| Sakai, K | 1 |
| Irie, K | 1 |
| Terasawa, T | 1 |
| Shimoyama, T | 1 |
| Kawahara, T | 2 |
| Okumura, T | 1 |
| Yamamoto, M | 1 |
| Yasutake, K | 1 |
| Ishiwata, K | 1 |
| Takahashi, T | 2 |
| Iwata, R | 1 |
| Tomura, M | 1 |
| Tada, M | 1 |
| Itoh, J | 1 |
| Ido, T | 1 |
| Kato, M | 1 |
| Sawai, K | 1 |
| Noguchi, A | 1 |
| Minato, H | 1 |
| Dexeus, FH | 1 |
| Logothetis, CJ | 1 |
| Sella, A | 1 |
| Amato, R | 1 |
| Kilbourn, R | 1 |
| Ogden, S | 1 |
| Striegel, A | 1 |
| Kwan, J | 1 |
| Newman, RA | 1 |
| Tsuchiya, Y | 1 |
| Kobayakawa, K | 1 |
| Lokich, J | 1 |
| Moore, C | 1 |
| Anderson, N | 1 |
| Bern, M | 1 |
| Iigo, M | 2 |
| Miwa, M | 3 |
| De Clercq, E | 1 |
| Damascelli, B | 1 |
| Marchianò, A | 1 |
| Spreafico, C | 1 |
| Lutman, R | 1 |
| Salvetti, M | 1 |
| Bonalumi, MG | 1 |
| Mauri, M | 1 |
| Garbagnati, F | 1 |
| Del Nero, A | 1 |
| Comeri, G | 1 |
| von Roemeling, R | 2 |
| Lanning, RM | 1 |
| Rabatin, JT | 2 |
| Tsai, CM | 1 |
| Gazdar, AF | 1 |
| Allegra, C | 1 |
| Perng, RP | 1 |
| Kramer, BS | 1 |
| Nakajima, Y | 1 |
| Araki, E | 1 |
| Mercer, JR | 3 |
| Xu, LH | 1 |
| Matsuda, M | 1 |
| Nagao, K | 1 |
| Baba, K | 1 |
| Nishimura, R | 1 |
| Matsuoka, Y | 1 |
| Ueno, Y | 1 |
| Morinaga, H | 1 |
| Nagase, H | 1 |
| Kawano, H | 1 |
| Schwartz, SI | 1 |
| Jones, LS | 1 |
| McCune, CS | 1 |
| Drings, P | 1 |
| Calcanis, A | 1 |
| Nakao, I | 1 |
| Saito, T | 1 |
| Kimura, K | 1 |
| Wakui, A | 1 |
| Yokoyama, M | 1 |
| Kanamaru, R | 1 |
| Furue, H | 1 |
| Komita, T | 1 |
| Ohta, K | 1 |
| Murakami, M | 2 |
| Lee, YW | 1 |
| Sears, HF | 1 |
| Shen, JW | 1 |
| Herlyn, M | 1 |
| Atkinson, B | 1 |
| Engstrom, PF | 1 |
| Koprowski, H | 1 |
| Ota, K | 1 |
| Yasue, M | 1 |
| Hoshino, A | 1 |
| Kamiya, O | 1 |
| Kinoshita, T | 1 |
| Hiraiwa, K | 1 |
| Hachisuka, K | 1 |
| Yamaguchi, A | 1 |
| Boothman, DA | 1 |
| Briggle, TV | 1 |
| Fujimoto, S | 1 |
| Wang, Y | 1 |
| Ogawa, M | 1 |
| Ryu, M | 1 |
| Matsuura, N | 1 |
| Fujimoto, K | 2 |
| Fukuda, H | 2 |
| Fraley, EE | 1 |
| Abe, Y | 1 |
| Matsuzawa, T | 1 |
| Ito, M | 1 |
| Fujiwara, T | 1 |
| Yamaguchi, K | 1 |
| Hatazawa, J | 1 |
| Kubota, K | 1 |
| Sato, T | 1 |
| Watanuki, S | 1 |
| Yano, T | 1 |
| Aoyama, A | 1 |
| Shibuya, M | 1 |
| Shimabukuro, Z | 1 |
| Ootsuka, M | 1 |
| Niitani, H | 1 |
| DeConti, RC | 1 |
| Kaplan, SR | 1 |
| Papac, RJ | 1 |
| Selawry, OS | 1 |
| Miller, E | 1 |
| Van Dyk, JJ | 1 |
| Clarkson, BD | 1 |
| Duschinsky, R | 1 |
| Keller, O | 1 |
| La Sala, E | 1 |
| Krakoff, IH | 1 |
| Baden, H | 1 |
| Kenis, Y | 1 |
6 reviews available for floxuridine and Lung Neoplasms
| Article | Year |
|---|---|
Isolated lung perfusion with antineoplastic agents for pulmonary metastases.
Topics: Animals; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antine | 1998 |
Adrenalectomy for solitary adrenal metastasis from colorectal carcinoma.
Topics: Adrenal Gland Neoplasms; Adrenalectomy; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy | 2000 |
Radiation sensitizers.
Topics: Animals; Antineoplastic Agents; Bromodeoxycytidine; Bromodeoxyuridine; Carcinoma; Deoxyuridine; Dogs | 1976 |
Rationale for adjuvant chemotherapy.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Carmustine; Cyclophosphamide; Cytarabine; Doxorubi | 1977 |
Monochemotherapy of bronchogenic carcinoma withs special reference to cell type.
Topics: Adenocarcinoma; Alkylating Agents; Antineoplastic Agents; Carcinoma, Bronchogenic; Cytarabine; Dacti | 1973 |
Chemotherapy of residual disease in solid tumours.
Topics: Colonic Neoplasms; Cyclophosphamide; Floxuridine; Fluorouracil; Head and Neck Neoplasms; Humans; Lun | 1971 |
14 trials available for floxuridine and Lung Neoplasms
| Article | Year |
|---|---|
Pharmacokinetics of gemcitabine in non-small-cell lung cancer patients: impact of the 79A>C cytidine deaminase polymorphism.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcin | 2010 |
The ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase in tumour tissues of patients with metastatic gastric cancer is predictive of the clinical response to 5'-deoxy-5-fluorouridine.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Dihydrouracil Dehydrogenase (NADP); Enzyme-Linked Immu | 2004 |
Sequential treatment with irinotecan and doxifluridine: optimal dosing schedule in murine models and in a phase I study for metastatic colorectal cancer.
Topics: Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neopl | 2005 |
[Evaluation of safety and efficacy for bi-weekly Docetaxel and 5'-DFUR combination therapy in patients with advanced or recurrent breast cancer--Phase I study].
Topics: Administration, Oral; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Bone Ne | 2006 |
Simultaneous determination of gemcitabine and its main metabolite, dFdU, in plasma of patients with advanced non-small-cell lung cancer by high-performance liquid chromatography-tandem mass spectrometry.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Smal | 2008 |
Multi-center phase II study for combination therapy with paclitaxel/doxifluridine to treat advanced/recurrent gastric cancer showing resistance to S-1 (OGSG 0302).
Topics: Adenocarcinoma; Aged; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Disease-Free | 2008 |
[The effect of combination treatment consisted of 5'-deoxy-5-fluorouridine and medroxyprogesterone acetate for recurrent breast cancer patient].
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; B | 1995 |
Phase I study of 5-day continuous infusion fluorodeoxyuridine and high-dose folinic acid with oral hydroxyurea.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 1994 |
Phase II study of oral doxifluridine in elderly patients with advanced non-small-cell lung cancer.
Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Sm | 1996 |
Doxifluridine in colorectal cancer patients resistant to 5-fluorouracil (5-FU) containing regimens.
Topics: Administration, Oral; Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents | 1997 |
[Clinical application of FdUrd to meningeal dissemination of malignant tumors].
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Brain Neoplasms; Breast Neoplasms; Drug Admin | 1998 |
[Combination chemotherapy of doxifluridine plus mitomycin C for colorectal lung metastasis--phase II study].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2001 |
[Combination therapy of doxifluridine (5'-DFUR) + cyclophosphamide (CPA) + tamoxifen (TAM) for advanced or recurrent breast cancer. Joint Research Group in the Osaka Area for Combination Therapy of 5'-DFUR with Other Drugs].
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 1992 |
Circadian-shaped infusions of floxuridine for progressive metastatic renal cell carcinoma.
Topics: Adult; Aged; Carcinoma, Renal Cell; Circadian Rhythm; Female; Floxuridine; Humans; Infusion Pumps; K | 1990 |
100 other studies available for floxuridine and Lung Neoplasms
| Article | Year |
|---|---|
Synthesis and biological activity of 5-fluoro-2',3'-dideoxy-3'-fluorouridine and its 5'-phosphate.
Topics: Animals; Cell Division; Deoxyuracil Nucleotides; Dideoxynucleosides; Dideoxynucleotides; Floxuridine | 1984 |
Debulking treatment with CT-guided percutaneous radiofrequency ablation and hepatic artery infusion of floxuridine improves survival of patients with unresectable pulmonary and hepatic metastases of colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Catheter Ablation; Colorectal Neoplasms; Combi | 2014 |
Mitochondrial induced and self-monitored intrinsic apoptosis by antitumor theranostic prodrug: in vivo imaging and precise cancer treatment.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Floxuridine; Humans; Lung Neoplasms; Mi | 2014 |
Salvage combination chemotherapy with floxuridine, dactinomycin, etoposide, and vincristine (FAEV) for patients with relapsed/chemoresistant gestational trophoblastic neoplasia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Dactinomycin; Dru | 2011 |
[A case of gastric cancer with lung, Virchow and para-aortic lymph node metastases treated successfully using PTX/5'-DFUR].
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Combined Modality Therapy; Fatal Outcome; Flo | 2011 |
NF-kappaB activation within macrophages leads to an anti-tumor phenotype in a mammary tumor lung metastasis model.
Topics: Animals; CD11b Antigen; Chemokine CXCL9; Female; Floxuridine; I-kappa B Kinase; Lung; Lung Neoplasms | 2011 |
Inhibition of dUTPase induces synthetic lethality with thymidylate synthase-targeted therapies in non-small cell lung cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; | 2012 |
[A case of colon metastasis to the lung treated successfully with combined chemotherapy of CPT-11 and 5'-DFUR].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Administration Sc | 2002 |
[A case of advanced recurrent breast cancer responding to treatment with weekly docetaxel combined with doxorubicin].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Combine | 2003 |
[A case of multiple lung metastases of colon cancer with long-term survival following 5'-DFUR and cimetidine therapy].
Topics: Adenocarcinoma; Adjuvants, Immunologic; Aged; Antimetabolites, Antineoplastic; Cimetidine; Colonic N | 2003 |
FURTHER CLINICAL COMPARISON BETWEEN 5-FLUOROURACIL (5-FU) AND 5-FLUORO-2' -DEOXYURIDINE (5-FUDR).
Topics: Brain Neoplasms; Breast Neoplasms; Diarrhea; Floxuridine; Fluorouracil; Geriatrics; Humans; Liver Ne | 1963 |
PROTRACTED AMBULATORY INFUSION CANCER CHEMOTHERAPY BY THE WATKINS CHRONOMETRIC INFUSOR.
Topics: Adenoma; Antineoplastic Agents; Breast Neoplasms; Carcinosarcoma; Colonic Neoplasms; Dermatitis, Exf | 1964 |
SYSTEMIC CHEMOTHERAPY FOR CNS METASTASES OF SOLID TUMORS.
Topics: Adenocarcinoma; Brain Neoplasms; Breast Neoplasms; Cyclophosphamide; Drug Therapy; Floxuridine; Fluo | 1965 |
[A case of advanced breast cancer with multiple lung, bone and lymph node metastases successfully treated with 5'-DFUR alone].
Topics: Aged; Antimetabolites, Antineoplastic; Bone Neoplasms; Breast Neoplasms; Combined Modality Therapy; | 2003 |
[A case of breast cancer with lung and bone metastasis treated successfully by oral combination chemotherapy of 5'-deoxy-5-fluorouridine and cyclophosphamide].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Carcinoma, Ductal, | 2003 |
S-1-induced, prolonged complete regression of lung metastasis from gastric cancer refractory to 5'-DFUR: a case report with pharmacokinetic study.
Topics: Adenocarcinoma, Mucinous; Administration, Oral; Antimetabolites, Antineoplastic; Chemotherapy, Adjuv | 2004 |
[A case of recurrent breast cancer with multiple lung, adrenal, inferior vena cava tumor thrombus and bone metastases successfully treated with 5'-DFUR and hormonal therapy].
Topics: Adult; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplas | 2005 |
Correlations between antitumor activities of fluoropyrimidines and DPD activity in lung tumor xenografts.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cell L | 2005 |
[Long-term survival in a case of large bowel cancer--efficacy of CPT-11-based chemotherapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Color | 2005 |
The MMP-9 expression determined the efficacy of postoperative adjuvant chemotherapy using oral fluoropyrimidines in stage II or III colorectal cancer.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemo | 2006 |
[Combined chemotherapy with weekly Paclitaxel and doxifluridine for advanced and recurrent gastric cancers].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Female; F | 2006 |
[A case of recurrent gastric cancer effectively treated by combination chemotherapy of weekly paclitaxel and 5'- DFUR after showing resistance to weekly paclitaxel].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Combined Moda | 2006 |
[A treatment for pulmonary metastases from colorectal cancer by pre-operative CPT-11/5'-DFUR combination therapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; | 2006 |
Doxifluridine combined with weekly paclitaxel for second-line treatment in patients with gastric cancer resistant to TS-1.
Topics: Abdominal Neoplasms; Adrenal Gland Neoplasms; Adult; Aged; Aged, 80 and over; Antineoplastic Combine | 2007 |
[Evaluation of combination therapy of high-dose toremifene and oral chemotherapy].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine | 2007 |
Measurement of plasma concentration of gemcitabine and its metabolite dFdU in hemodialysis patients with advanced urothelial cancer.
Topics: Antimetabolites, Antineoplastic; Area Under Curve; Bone Neoplasms; Cystectomy; Deoxycytidine; Fatal | 2008 |
Antiproliferative action of a novel fluorinated uridine analog, 5'-deoxy-5-fluorouridine, measured in vitro and in vivo on four different murine tumor lines.
Topics: Animals; Cell Line; Drug Evaluation, Preclinical; Floxuridine; Isomerism; Lung Neoplasms; Lymphoma; | 1982 |
Intra-arterial chemotherapy using an implantable infusion pump and liver irradiation for the treatment of hepatic metastases.
Topics: Adult; Aged; Bone Neoplasms; Chemotherapy, Cancer, Regional Perfusion; Colonic Neoplasms; Drug Admin | 1982 |
[Phase I study of a new floxuridine derivative, 2'-deoxy-3', 5'-di-O-acetyl-5-fluoro-3-(3-methylbenzoyl)uridine (FF-705)].
Topics: Administration, Oral; Adult; Aged; Breast Neoplasms; Capsules; Drug Administration Schedule; Drug Ev | 1984 |
[Phase II study of FF-705 by Clinical Cooperative Study Group].
Topics: Administration, Oral; Adult; Aged; Breast Neoplasms; Capsules; Colonic Neoplasms; Drug Administratio | 1984 |
Potentiation of 5-fluoro-2'-deoxyuridine antineoplastic activity by the uridine phosphorylase inhibitors benzylacyclouridine and benzyloxybenzylacyclouridine.
Topics: Animals; Cell Line; Cell Survival; Drug Evaluation, Preclinical; Drug Synergism; Female; Floxuridine | 1984 |
New approach to metabolism of 5'-deoxy-5-fluorouridine in humans with fluorine-19 NMR.
Topics: Antineoplastic Agents; Female; Floxuridine; Fluorine; Humans; Kinetics; Lung Neoplasms; Magnetic Res | 1984 |
[5'-Deoxy-5-fluorouridine enzymatic activation from the masked compound to 5-fluorouracil in human malignant tissues].
Topics: Administration, Oral; Aged; Animals; Antineoplastic Agents; Enzyme Activation; Female; Floxuridine; | 1984 |
Phase II study of oral administration of 5'-deoxy-5-fluorouridine (5'-DFUR) for solid tumors.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Bone Marrow; Drug Evaluation; Female; Flox | 1984 |
Tumor inhibitory effects of a new fluorouracil derivative: 5'-deoxy-5-fluorouridine.
Topics: Animals; Female; Floxuridine; Lethal Dose 50; Lung Neoplasms; Mice; Neoplasms, Experimental; Sarcoma | 1980 |
[Chemotherapy for older cancer patients].
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Ce | 1993 |
Steroid-responsive interstitial lung disease in patients receiving 2'-deoxy-5-fluorouridine-infusion chemotherapy. A report of three cases.
Topics: Aged; Carcinoma, Renal Cell; Cough; Dyspnea; Female; Fever; Floxuridine; Forced Expiratory Volume; H | 1995 |
Selective inhibition of spontaneous pulmonary metastasis of Lewis lung carcinoma by 5'-deoxy-5-fluorouridine.
Topics: Animals; Antineoplastic Agents; Carcinoma, Lewis Lung; Cell Division; Collagenases; Cytokines; Drug | 1995 |
Isolated lung perfusion with FUDR is an effective treatment for colorectal adenocarcinoma lung metastases in rats.
Topics: Adenocarcinoma; Animals; Chemotherapy, Cancer, Regional Perfusion; Colorectal Neoplasms; Female; Flo | 1995 |
[A case of pulmonary metastasis from colon cancer successfully treated with high-dose 5'-DFUR].
Topics: Adenocarcinoma; Antineoplastic Agents; Colectomy; Colonic Neoplasms; Combined Modality Therapy; Drug | 1995 |
Characterization of organ-specific immunoliposomes for delivery of 3',5'-O-dipalmitoyl-5-fluoro-2'-deoxyuridine in a mouse lung-metastasis model.
Topics: Animals; Antibodies, Monoclonal; Antibody Specificity; Antineoplastic Agents; Binding Sites, Antibod | 1995 |
[A case of complete response of breast cancer with pulmonary metastases to combination therapy of 5'-DFUR and MPA].
Topics: Breast Neoplasms; Chemotherapy, Adjuvant; Drug Therapy, Combination; Female; Floxuridine; Humans; Lu | 1994 |
[A case of advanced breast cancer with multiple lung metastases responding well to postoperative combined administration of doxifluridine (5'-DFUR) and tamoxifen].
Topics: Adenocarcinoma, Papillary; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; F | 1994 |
[Antitumor activity of various cytostatics in mice bearing murine advanced tumors].
Topics: Animals; Antineoplastic Agents; Cachexia; Cyclophosphamide; Drug Screening Assays, Antitumor; Floxur | 1993 |
[A case of advanced gastric cancer with liver and lung metastasis effectively treated by combined chemo-immunotherapy of MMC, 5'-DFUR, OK-432].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dru | 1993 |
[A case of bilateral pulmonary metastasis from rectal cancer successfully treated with resection after high-dose 5'-DFUR plus MMC combination chemotherapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Female; Flox | 1993 |
Isolated lung perfusion with FUDR in the rat: pharmacokinetics and survival.
Topics: Animals; Antimetabolites, Antineoplastic; Chemotherapy, Cancer, Regional Perfusion; Chromatography, | 1996 |
[PyNPase activity in primary and metastatic colorectal cancer].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Colorectal Neoplasms; Female; Floxuridine; Humans; L | 1997 |
[Complete tumor regression obtained by chemoendocrine therapy including toremifene in two cases of pulmonary metastasis of breast cancer with a history of tamoxifen treatment].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; | 1997 |
[A case of complete response of metastasis of cervical cancer with a combination of CBDCA and 5'-DFUR].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Female; Floxuridine; Humans; Lung Neopl | 1998 |
[Three cases of colorectal cancer with lung metastasis successfully treated with combination chemotherapy using 5'-DFUR and MMC].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administration Sch | 1998 |
[Combination of 5'-DFUR and MMC for recurrent rectal cancer with pulmonary metastasis].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; | 1999 |
[Effective chemo-endocrine combination therapy for obstructive-jaundice caused by multiple liver metastasis of recurrent breast cancer--a case report].
Topics: Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neopla | 1999 |
[Endocrine chemotherapy (high-dose toremifene + 5'-DFUR) found markedly effective for 2 cases of metastatic breast cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Female; Flox | 1999 |
[A patient with multiple pulmonary metastases from colonic cancer who survived for 5 years by effectual administration of 5'-DFUR].
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Carcinoembryonic Antigen; Colonic Neopl | 2000 |
[Chemotherapy with mitoxantrone for the treatment of recurrent breast cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Drug Administratio | 2000 |
A case of metastatic breast cancer achieving complete response by combination therapy with 5'-deoxy-5-fluorouridine and cyclophosphamide.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biotransformation; Breast Neoplasms; Carcinoma, Duct | 2000 |
[A case of breast cancer with multiple organ metastases responding remarkably to combination therapy of CAF (cyclophosphamide, adriamycin and 5-FU), 5'-DFUR and MPA (medroxyprogesterone acetate)].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Combined M | 2000 |
[Weekly low dose CPT-11 for multiple lung metastases of colon cancer on an out-patient treatment: a case report].
Topics: Adult; Ambulatory Care; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptoth | 2001 |
[A case of lung metastasis from colon cancer treated successfully with combined chemotherapy of CPT-11 and 5'-DFUR].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colonic Neopla | 2001 |
[A 5'-DFUR + CPA + THP therapy that was effective for paclitaxel-refractory pulmonary metastasis of breast cancer--a case report].
Topics: Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neo | 2002 |
[Antimetastatic and antitumor effects of fluoropyrimidines alone and combined with taxanes in a murine model of breast cancer metastatic to the lung].
Topics: Aminoacridines; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brea | 2002 |
gamma-Hydroxybutyric acid and 5-fluorouracil, metabolites of UFT, inhibit the angiogenesis induced by vascular endothelial growth factor.
Topics: Angiogenesis Inhibitors; Animals; Antimetabolites, Antineoplastic; Breast Neoplasms; Carcinoma; Carc | 2001 |
Biochemical and molecular effects of UCN-01 in combination with 5-fluorodeoxyuridine in A431 human epidermoid cancer cells.
Topics: Alkaloids; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Cell Cycle; Cell Survival; Deo | 2002 |
Bioassay of alkyl halides and nucleotide base analogs by pulmonary tumor response in strain A mice.
Topics: Adenoma; Alkanes; Animals; Biological Assay; Bromodeoxyuridine; Carcinogens; Deoxyuridine; Female; F | 1975 |
Susceptibilities of normal and malignant human lung cells in culture to the cytocidal action of antitumor agents.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line; Cell Survival; Doxorubicin; Drug Evaluat | 1978 |
Tumor uptake of radiolabeled pyrimidine bases and pyrimidine nucleosides in animal models--II. 6-[3H]-5-fluoro-2'-deoxyuridine.
Topics: Animals; Carcinoma, Ehrlich Tumor; Floxuridine; Half-Life; Lung Neoplasms; Male; Mice; Neoplasm Tran | 1979 |
In vitro enhancement of fluoropyrimidine-induced cytotoxicity by leucovorin in colorectal and gastric carcinoma cell lines but not in non-small-cell lung carcinoma cell lines.
Topics: Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Cell Survival; Colony-Forming Units Assay; Colorecta | 1992 |
[A case of multiple pulmonary metastases from duodenal cancer showing partial response using 5'-DFUR and a small dose of MMC].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Duodenal Neoplasms; Female; Fl | 1992 |
Tumor diagnosis by PET: potential of seven tracers examined in five experimental tumors including an artificial metastasis model.
Topics: Animals; Carbon Radioisotopes; Deoxyglucose; Diagnosis, Differential; Disease Models, Animal; Floxur | 1992 |
[Two cases of pulmonary metastasis of colorectal cancer successfully treated with oral 5'-DFUR].
Topics: Adenocarcinoma; Administration, Oral; Aged; Antineoplastic Agents; Drug Administration Schedule; Fem | 1992 |
Circadian infusion of floxuridine in patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Carcinoma, Renal Cell; Drug Administration Schedule; Female; Floxuridine; Humans; Infus | 1991 |
[A case of pulmonary metastasis from colon cancer responding completely to high-dose 5'-DFUR plus MMC combination chemotherapy].
Topics: Adenocarcinoma; Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic | 1991 |
Infusion of floxuridine plus etoposide plus cisplatin in human malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Ci | 1991 |
Optimal treatment regimens for 5'-deoxy-5-fluorouridine, with or without (E)-5-(2-bromovinyl)-2'-deoxyuridine, against various tumors in mice.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Antiviral Agents; Bromodeoxyuridine; Colonic Neoplas | 1990 |
Circadian continuous chemotherapy of renal cell carcinoma with an implantable, programmable infusion pump.
Topics: Adult; Aged; Carcinoma, Renal Cell; Drug Evaluation; Female; Floxuridine; Humans; Infusion Pumps, Im | 1990 |
Enhancement of fluorinated pyrimidine-induced cytotoxicity by leucovorin in human lung cancer cell lines.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Carcinoma, Squamous Cell; Cell Line; Dose-Respo | 1990 |
Enhanced antitumor effect of 5'-deoxy-5-fluorouridine by oral administration with L-cysteine.
Topics: Adenocarcinoma; Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Chrom | 1989 |
Synthesis and tumor uptake of 5-82Br- and 5-131I-labeled 5-halo-1-(2-fluoro-2-deoxy-beta-D-ribofuranosyl)uracils.
Topics: Animals; Biological Transport; Bromine Radioisotopes; Chemical Phenomena; Chemistry; DNA; Female; Fl | 1989 |
[A case of multiple pulmonary metastases from rectal cancer which responded completely to combination chemotherapy using 5'-DFUR and MMC].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Tolerance; Floxuridine; H | 1989 |
Assessment of treatment of intrahepatic malignancies using chemotherapy via an implantable pump.
Topics: Adenoma, Islet Cell; Aged; alpha-Fetoproteins; Carcinoma, Hepatocellular; Catheterization; Catheters | 1985 |
[Furtulon (doxifluridine) in the treatment of non-small cell bronchial carcinoma].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small | 1987 |
[Phase I study of 5'-deoxy-5-fluorouridine (5'-DFUR)].
Topics: Administration, Oral; Adult; Aged; Anorexia; Antineoplastic Agents; Colonic Neoplasms; Drug Administ | 1985 |
Tumour uptake of radiolabelled pyrimidine bases and pyrimidine nucleosides in animal models. IX. Radiolabelled 1-(2'-fluoro-2'-deoxy-beta-D-ribofuranosyl)uracil and 1-(2'-chloro-2'-deoxy-beta-D-ribofuranosyl)uracil.
Topics: Animals; Carbon Radioisotopes; Carcinoma 256, Walker; Chlorine; Deoxyuridine; Floxuridine; Lung Neop | 1986 |
Circulating tumor markers and assessment of response to intrahepatic chemotherapy of colon carcinoma.
Topics: Adult; Aged; Antigens, Neoplasm; Antigens, Tumor-Associated, Carbohydrate; Carcinoembryonic Antigen; | 1985 |
Modulation of the effects of fluoropyrimidines on toxicity and tumor inhibition in rodents by uridine and thymidine.
Topics: Animals; Dose-Response Relationship, Drug; Female; Floxuridine; Fluorouracil; Leukemia L1210; Lung N | 1986 |
[Clinical trial of 5'-deoxy-5-fluorouridine in malignant tumors under cooperative study (phase II study)].
Topics: Aged; Aged, 80 and over; Breast Neoplasms; Colonic Neoplasms; Drug Evaluation; Female; Floxuridine; | 1986 |
Drug-induced perturbations in the in vivo distribution of oncological radiotracers--I. 5-Fluoro-6-3H-2'-deoxyuridine influenced by nitrobenzylthioinosine 5'-phosphate (NBMPR-P).
Topics: Animals; Floxuridine; Inosine; Lung Neoplasms; Male; Mice; Mice, Inbred Strains; Neoplasm Transplant | 1986 |
Synthesis and tumor uptake of 5-halo-1-(2'-fluoro-2'-deoxy-beta-D-ribofuranosyl)[2-14C]uracils.
Topics: Animals; Antimetabolites, Antineoplastic; Biological Transport; Carcinoma; Carrier Proteins; Erythro | 1987 |
Tumor-selective metabolism of 5-fluoro-2'-deoxycytidine coadministered with tetrahydrouridine compared to 5-fluorouracil in mice bearing Lewis lung carcinoma.
Topics: Animals; Antimetabolites; Deoxycytidine; Female; Floxuridine; Fluorouracil; Lung Neoplasms; Mice; Te | 1987 |
Enhanced antitumor activity of 5'-deoxy-5-fluorouridine against Lewis lung carcinoma in aged hybrid (C57BL/6 x DBA/2) F1 mice.
Topics: Age Factors; Animals; Antineoplastic Agents; Floxuridine; Hybridization, Genetic; Lethal Dose 50; Lu | 1987 |
[Antitumor activity and toxicity to the immune system and intestine, of the fluorinated pyrimidines FUra, 5'-DFUR, tegafur and UFT].
Topics: Animals; Antibody Formation; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Bone Marro | 1988 |
[Comparative studies on the antitumor activity of the fluorinated pyrimidines 5'-DFUR, tegafur, UFT and FUra on various murine tumors].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Floxuridine; Fluorouraci | 1988 |
Circadian-based infusional chrono-chemotherapy controls progressive metastatic renal cell carcinoma.
Topics: Adult; Aged; Carcinoma, Renal Cell; Circadian Rhythm; Dose-Response Relationship, Drug; Female; Flox | 1988 |
[Cancer detection with 18F-5-fluorodeoxyuridine--a new cancer diagnostic agent reflecting nucleic acid metabolism].
Topics: Carcinoma, Small Cell; Carcinoma, Squamous Cell; Floxuridine; Fluorine; Humans; Lung Neoplasms; Nucl | 1985 |
[Experimental results of survivals with different dose schedule of 5-FU and 5'-DFUR].
Topics: Animals; Antineoplastic Agents; Drug Administration Schedule; Floxuridine; Fluorouracil; Lung Neopla | 1985 |
Continuous intravenous infusions of 5-fluoro-2'-deoxyuridine in the treatment of solid tumors.
Topics: Breast Neoplasms; Diarrhea; Drug Eruptions; Female; Floxuridine; Gastrointestinal Neoplasms; Hemangi | 1973 |
The clinical effects of prolonged intravenous infusion of 5-fluoro-2'-deoxyuridine.
Topics: Adenoma, Islet Cell; Aged; Breast Neoplasms; Carcinoma, Squamous Cell; Colonic Neoplasms; Female; Fl | 1965 |
Clinical evaluation of 5-bromo-5-fluoro-6-methoxy-dihydro-2'-deoxyuridine.
Topics: Adenocarcinoma; Adult; Aged; Animals; Bromodeoxyuridine; Carcinoma; Carcinoma, Hepatocellular; Carci | 1967 |
[Continuous intra-arterial infusion of 5-fluor-2-deoxyuridine in primary and metastatic liver cancer].
Topics: Adenoma, Bile Duct; Adult; Aged; Arteries; Carcinoma, Hepatocellular; Female; Floxuridine; Gastroint | 1968 |